• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps 250 Points; Crude Oil Rises Over 1%

    9/12/22 12:21:59 PM ET
    $AKTX
    $APGN
    $INM
    $KNTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Monday.

    The Dow traded up 0.80% to 32,408.75 while the NASDAQ rose 0.75% to 12,203.21. The S&P 500 also rose, gaining, 0.89% to 4,103.64.

    Also check this: Volatility In Markets Drops After US Stocks Record Weekly Gains


    Leading and Lagging Sectors

     

    • Energy shares jumped by 2.1% on Monday. Meanwhile, top gainers in the sector included ProFrac Holding Corp. (NASDAQ:PFHC), up 5% and Kinetik Holdings Inc. (NASDAQ:KNTK) up 5%.
    • In trading on Monday, communication services shares fell by 0.1%.


    Top Headline


    U.S. consumer inflation expectations for the year ahead dropped to 5.7% in August from 6.2% in the previous month. It was the lowest reading since October 2021.

     

    Equities Trading UP

     

    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares shot up 57% to $36.25 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
    • Shares of InMed Pharmaceuticals Inc. (NASDAQ:INM) got a boost, shooting 67% to $18.35 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares were also up, gaining 89% to $0.5220 after the company announced a 1-for-30 reverse stock split.

     

    Equities Trading DOWN

    • Apexigen, Inc. (NASDAQ:APGN) shares tumbled 15% to $6.49 after the company announced the presentation of new data from a Phase 2 trial evaluating sotigalimab in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction cancers.
    • Shares of Tuesday Morning Corporation (NASDAQ:TUEM) were down 24% to $0.2126 after the company secured commitment for strategic investment from a group led by Retail Ecommerce Ventures LLC, the owner of Pier 1 Imports and top consumer brands.
    • Akari Therapeutics, Plc (NASDAQ:AKTX) was down, falling 25% to $0.7799 after the company announced a $12.75 million registered direct offering.

    Also check out: Kroger, DocuSign And Other Big Gainers From Friday


    Commodities

    In commodity news, oil traded up 1.4% to $87.97, while gold traded up 0.7% at $1,740.00.


    Silver traded up 5.1% to $19.725 on Monday while copper rose 0.4% to $3.5810.



    Euro zone


    European shares were higher today. The eurozone’s STOXX 600 gained 1.61%, London’s FTSE 100 rose 1.53%, while Spain’s IBEX 35 Index rose 1.92%. The German DAX gained 2.16%, French CAC 40 rose 1.81% and Italy’s FTSE MIB Index gained 2.09%.

    Industrial production in the UK dropped by 0.3% from a month ago in July versus a 0.9% drop in the previous month. The country’s trade deficit also shrank to GBP 7.8 billion in July from GBP 11.4 billion a month ago. The British economy grew by 0.2% in July from the previous month, compared to a 0.6% decline in the prior month.

    Industrial production in Italy rose 0.4% from a month ago in July following a revised 2% decline in the prior month.

     

    Economics

     

    • U.S. consumer inflation expectations for the year ahead dropped to 5.7% in August from 6.2% in the previous month. It was the lowest reading since October 2021.
    • The Treasury will also auction 3-month bills and 10-year notes at 1:00 p.m. ET.


    Check out this: Bitcoin Surges Past $22,000, Here Are Other Crypto Movers That Should Be On Your Radar Today


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 97,095,090 cases with around 1,075,660 deaths. India confirmed a total of at least 44,500,580 cases and 528,160 deaths, while France reported over 34,718,130 COVID-19 cases with 154,460 deaths. In total, there were at least 613,950,810 cases of COVID-19 worldwide with more than 6,516,850 deaths.

    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX
    $APGN
    $INM
    $KNTK

    CompanyDatePrice TargetRatingAnalyst
    Kinetik Holdings Inc.
    $KNTK
    2/6/2026$43.00Buy → Hold
    Jefferies
    Kinetik Holdings Inc.
    $KNTK
    1/27/2026Outperform → Peer Perform
    Wolfe Research
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    Kinetik Holdings Inc.
    $KNTK
    1/5/2026$46.00Mkt Perform → Outperform
    Raymond James
    Kinetik Holdings Inc.
    $KNTK
    12/2/2025$41.00Buy
    Jefferies
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Kinetik Holdings Inc.
    $KNTK
    10/22/2025$45.00Peer Perform → Outperform
    Wolfe Research
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AKTX
    $APGN
    $INM
    $KNTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Ordemann William

    5 - Kinetik Holdings Inc. (0001692787) (Issuer)

    2/3/26 5:09:24 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    SEC Form 5 filed by Leland D Mark

    5 - Kinetik Holdings Inc. (0001692787) (Issuer)

    2/3/26 5:09:18 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    SEC Form 5 filed by Sugg Laura A

    5 - Kinetik Holdings Inc. (0001692787) (Issuer)

    2/3/26 5:09:12 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    $AKTX
    $APGN
    $INM
    $KNTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Welch Jamie bought $276,560 worth of shares (8,000 units at $34.57), increasing direct ownership by 0.22% to 3,687,791 units (SEC Form 4)

    4 - Kinetik Holdings Inc. (0001692787) (Issuer)

    11/10/25 6:17:16 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Officer Welch Jamie bought $195,650 worth of shares (5,000 units at $39.13), increasing direct ownership by 0.14% to 3,676,399 units (SEC Form 4)

    4 - Kinetik Holdings Inc. (0001692787) (Issuer)

    10/3/25 5:37:11 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    CEO Gaslightwala Abizer bought $19,540 worth of American Depositary Shares representing Ordinary Shares (21,000 units at $0.93), increasing direct ownership by 8% to 298,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    8/29/25 4:55:12 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $APGN
    $INM
    $KNTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline

    CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human studies Watch the "What This Means" video here TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that Abizer Gaslightwala, CEO of Akari Therapeutics, participated in a Virtual Investor "What This Means" interview focused on the Company's exp

    2/11/26 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    – Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the presentation, Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, will provide a corporate overview highlighting the Company's next-generation antibody drug conjugate platform and proprietary PH1 spliceosome-modulatin

    2/5/26 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

    Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology's most challenging and valuable solid tumor targets, CEACAM5 TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced the filing of a new U.S. provisional patent application (No. 63/958,508) covering its second pipeline candidate, AKTX-102, an ADC directed against CEACAM5 (Carcinoembry

    1/26/26 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $APGN
    $INM
    $KNTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kinetik downgraded by Jefferies with a new price target

    Jefferies downgraded Kinetik from Buy to Hold and set a new price target of $43.00

    2/6/26 8:09:48 AM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Kinetik downgraded by Wolfe Research

    Wolfe Research downgraded Kinetik from Outperform to Peer Perform

    1/27/26 8:41:35 AM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $APGN
    $INM
    $KNTK
    SEC Filings

    View All

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 8:51:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by InMed Pharmaceuticals Inc.

    10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 5:04:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $APGN
    $INM
    $KNTK
    Financials

    Live finance-specific insights

    View All

    Kinetik Increases Quarterly Dividend and Announces Financial Results Timing

    Kinetik Holdings Inc. (NYSE:KNTK) ("Kinetik" or the "Company") today announced that its Board of Directors has declared an increase to its quarterly cash dividend to $0.81 per share, or $3.24 per share on an annualized basis. The announced quarterly dividend represents an approximately 4% increase versus the prior quarterly dividend paid in October 2025. The dividend will be paid on Friday, February 13, 2026 to shareholders of record as of market close on Friday, February 6, 2026. Kinetik will host its fourth quarter 2025 results conference call on Thursday, February 26, 2026 at 8:00 am Central Time (9:00 am Eastern Time). The Company will issue its earnings release after market close

    1/22/26 4:15:00 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Kinetik Reports Third Quarter 2025 Financial and Operating Results and Revises 2025 Financial Guidance

    Kinetik Holdings Inc. (NYSE:KNTK) ("Kinetik" or the "Company") today reported financial results for the quarter ended September 30, 2025. Kinetik reported net income including noncontrolling interest of $15.5 million and $109.2 million for the three and nine months ended September 30, 2025, respectively. Kinetik generated Adjusted EBITDA1 of $242.6 million and $735.6 million, Distributable Cash Flow1 of $158.5 million and $468.8 million, and Free Cash Flow1 of $50.9 million and $179.2 million for the three and nine months ended September 30, 2025, respectively. Highlights Closed divestiture of 27.5% non-operated equity interest in EPIC Crude Holdings, LP ("EPIC Crude") Achieved full c

    11/5/25 5:15:00 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

    VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this studyVentyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences,

    10/22/25 4:02:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $APGN
    $INM
    $KNTK
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

    BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. "The formation of our SAB marks an important step in advancing Akari's scientific and clinical strategy, and we are honored to welcome Dr. Sara Hurvitz as its inaugural member," commented Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "In addition to her wealth of knowledge around ADCs, Dr. Hurvitz brings exceptional clinical expertise in the management of can

    10/30/25 8:35:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interactive Brokers Group Set to Join S&P 500, Talen Energy to Join S&P MidCap 400 and Kinetik Holdings to Join S&P SmallCap 600

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Group Inc. (NASD: IBKR) will replace Walgreens Boots Alliance Inc. (NASD: WBA) in the S&P 500, and Talen Energy Corp. (NASD: TLN) will replace Interactive Brokers Group in the S&P MidCap 400 effective prior to the opening of trading on Thursday, August 28. Sycamore Partners is acquiring Walgreens Boots Alliance in a deal expected to be completed soon, pending final closing conditions.  Kinetik Holdings Inc. (NYSE:KNTK) will replace Pacific Premier Bancorp Inc. (NASD: PPBI) in the S&P SmallCap 600 ef

    8/25/25 5:41:00 PM ET
    $COLB
    $IBKR
    $KNTK
    Major Banks
    Finance
    Investment Bankers/Brokers/Service
    Natural Gas Distribution

    Kinetik Announces Dual Listing on NYSE Texas

    Kinetik Holdings Inc. (NYSE:KNTK) ("Kinetik" or the "Company") today announced the dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange headquartered in Dallas, Texas. Kinetik will maintain its primary listing on the New York Stock Exchange (the "NYSE") and will commence trading on July 18, 2025 under the same ticker symbol, "KNTK," on NYSE Texas. "We are excited to join NYSE Texas as a Founding Member," said Jamie Welch, Kinetik's President & Chief Executive Officer. "We are proud of our deep roots in Texas with significant operations spanning the Permian Basin and headquarters in Houston and Midland. We look forward to further strengtheni

    7/17/25 8:52:00 AM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    $AKTX
    $APGN
    $INM
    $KNTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care